These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 30776909

  • 1. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
    Charles-Edwards G, Amaral N, Sleigh A, Ayis S, Catibog N, McDonagh T, Monaghan M, Amin-Youssef G, Kemp GJ, Shah AM, Okonko DO.
    Circulation; 2019 May 21; 139(21):2386-2398. PubMed ID: 30776909
    [Abstract] [Full Text] [Related]

  • 2. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
    Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P.
    J Am Coll Cardiol; 2008 Jan 15; 51(2):103-12. PubMed ID: 18191732
    [Abstract] [Full Text] [Related]

  • 3. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
    Gybel-Brask M, Seeberg J, Thomsen LL, Johansson PI.
    Transfusion; 2018 Apr 15; 58(4):974-981. PubMed ID: 29424441
    [Abstract] [Full Text] [Related]

  • 4. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M.
    Pharmacotherapy; 2016 Apr 15; 36(4):402-14. PubMed ID: 26927900
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia
.
    Biggar P, Leistikow F, Walper A.
    Clin Nephrol; 2016 Dec 15; 86 (2016)(12):310-318. PubMed ID: 27737531
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
    van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A, EFFECT-HF Investigators.
    Circulation; 2017 Oct 10; 136(15):1374-1383. PubMed ID: 28701470
    [Abstract] [Full Text] [Related]

  • 11. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE, Lombraña A, Duarte P, Di Gennaro F.
    J Am Coll Cardiol; 2007 Oct 23; 50(17):1657-65. PubMed ID: 17950147
    [Abstract] [Full Text] [Related]

  • 12. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
    Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, Nijhawan S, Thomsen LL.
    Am J Gastroenterol; 2013 Dec 23; 108(12):1877-88. PubMed ID: 24145678
    [Abstract] [Full Text] [Related]

  • 13. Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure.
    Lewis GD, Semigran MJ, Givertz MM, Malhotra R, Anstrom KJ, Hernandez AF, Shah MR, Braunwald E.
    Circ Heart Fail; 2016 May 23; 9(5):. PubMed ID: 27140203
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
.
    Jensen G, Gøransson LG, Fernström A, Furuland H, Christensen JH.
    Clin Nephrol; 2019 Apr 23; 91(4):246-253. PubMed ID: 30614439
    [Abstract] [Full Text] [Related]

  • 16. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
    Bhandari S, Kalra PA, Kothari J, Ambühl PM, Christensen JH, Essaian AM, Thomsen LL, Macdougall IC, Coyne DW.
    Nephrol Dial Transplant; 2015 Sep 23; 30(9):1577-89. PubMed ID: 25925701
    [Abstract] [Full Text] [Related]

  • 17. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial.
    Ambrosy AP, Lewis GD, Malhotra R, Jones AD, Greene SJ, Fudim M, Coles A, Butler J, Sharma A, Hernandez AF, Mentz RJ.
    J Cardiovasc Med (Hagerstown); 2019 Apr 23; 20(4):223-225. PubMed ID: 30540649
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.